Rising Pharma
As of the edition of 20 October 2026, Rising Pharma runs 12 drugs, 12 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 12 |
| Total | 12 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Acetaminophen | none listed | 17 |
| Fentanyl | none listed | 6 |
| Tretinoin | none listed | 3 |
| Ketoconazole | none listed | 2 |
| Sufentanil | none listed | 2 |
| Atropine | none listed | 12 |
| Indomethacin | none listed | 3 |
| Azelastine | none listed | 0 |
| Alfentanil | none listed | 1 |
| Droperidol | none listed | 2 |
| Chlorothiazide | none listed | 0 |
| Mafenide | none listed | 0 |
A route B row is one company at one target.